Eliana Merle
Stock Analyst at UBS
(2.99)
# 1,177
Out of 4,502 analysts
50
Total ratings
37.5%
Success rate
3.51%
Average return
Main Sectors:
Top Industries:
23 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $253 → $288 | $237.88 | +21.07% | 1 | Jun 28, 2024 | |
| ZNTL Zentalis Pharmaceuticals | Downgrades: Neutral | $28 → $5 | $4.36 | +14.68% | 3 | Jun 20, 2024 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $51 → $47 | $26.70 | +76.03% | 2 | May 28, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $89 → $85 | $38.88 | +118.62% | 5 | May 8, 2024 | |
| MRNA Moderna | Maintains: Buy | $143 → $151 | $120.40 | +25.42% | 3 | May 7, 2024 | |
| KOD Kodiak Sciences | Maintains: Neutral | $3 → $5 | $3.22 | +55.28% | 3 | Apr 4, 2024 | |
| TERN Terns Pharmaceuticals | Maintains: Buy | $19 → $18 | $8.79 | +104.78% | 2 | Mar 27, 2024 | |
| BNTX BioNTech SE | Maintains: Neutral | $110 → $101 | $84.68 | +19.27% | 3 | Mar 27, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $337 → $410 | $283.46 | +44.64% | 2 | Mar 15, 2024 | |
| AKRO Akero Therapeutics | Maintains: Buy | $39 → $42 | $28.32 | +48.31% | 3 | Mar 5, 2024 | |
| RAPT RAPT Therapeutics | Downgrades: Neutral | $61 → $10 | $3.12 | +220.51% | 1 | Feb 22, 2024 | |
| RVMD Revolution Medicines | Initiates: Buy | $40 | $45.56 | -12.20% | 1 | Dec 20, 2023 | |
| ANAB AnaptysBio | Maintains: Neutral | $28 → $21 | $37.23 | -43.59% | 3 | Nov 2, 2023 | |
| ETNB 89bio | Maintains: Buy | $36 → $25 | $9.66 | +158.80% | 2 | Oct 12, 2023 | |
| QURE uniQure | Maintains: Buy | $45 → $42 | $8.57 | +390.08% | 4 | May 19, 2023 | |
| CVAC CureVac | Upgrades: Buy | $18 | $3.64 | +394.51% | 1 | Jan 19, 2023 | |
| GOSS Gossamer Bio | Maintains: Buy | $19 → $8 | $1.09 | +633.94% | 2 | Dec 7, 2022 | |
| GLUE Monte Rosa Therapeutics | Initiates: Buy | $22 | $4.67 | +371.09% | 1 | Oct 13, 2022 | |
| RGNX REGENXBIO | Maintains: Buy | $51 → $47 | $14.39 | +226.62% | 1 | Jun 23, 2022 | |
| FOLD Amicus Therapeutics | Initiates: Buy | n/a | $10.26 | - | 2 | May 21, 2021 | |
| KYMR Kymera Therapeutics | Initiates: Buy | n/a | $44.04 | - | 1 | May 21, 2021 | |
| ARVN Arvinas | Initiates: Buy | n/a | $29.52 | - | 2 | May 21, 2021 | |
| GLPG Galapagos NV | Maintains: Neutral | n/a | $27.39 | - | 2 | Aug 19, 2020 |
Alnylam Pharmaceuticals
Jun 28, 2024
Maintains: Buy
Price Target: $253 → $288
Current: $237.88
Upside: +21.07%
Zentalis Pharmaceuticals
Jun 20, 2024
Downgrades: Neutral
Price Target: $28 → $5
Current: $4.36
Upside: +14.68%
BridgeBio Pharma
May 28, 2024
Maintains: Buy
Price Target: $51 → $47
Current: $26.70
Upside: +76.03%
Apellis Pharmaceuticals
May 8, 2024
Maintains: Buy
Price Target: $89 → $85
Current: $38.88
Upside: +118.62%
Moderna
May 7, 2024
Maintains: Buy
Price Target: $143 → $151
Current: $120.40
Upside: +25.42%
Kodiak Sciences
Apr 4, 2024
Maintains: Neutral
Price Target: $3 → $5
Current: $3.22
Upside: +55.28%
Terns Pharmaceuticals
Mar 27, 2024
Maintains: Buy
Price Target: $19 → $18
Current: $8.79
Upside: +104.78%
BioNTech SE
Mar 27, 2024
Maintains: Neutral
Price Target: $110 → $101
Current: $84.68
Upside: +19.27%
Madrigal Pharmaceuticals
Mar 15, 2024
Maintains: Buy
Price Target: $337 → $410
Current: $283.46
Upside: +44.64%
Akero Therapeutics
Mar 5, 2024
Maintains: Buy
Price Target: $39 → $42
Current: $28.32
Upside: +48.31%
RAPT Therapeutics
Feb 22, 2024
Downgrades: Neutral
Price Target: $61 → $10
Current: $3.12
Upside: +220.51%
Revolution Medicines
Dec 20, 2023
Initiates: Buy
Price Target: $40
Current: $45.56
Upside: -12.20%
AnaptysBio
Nov 2, 2023
Maintains: Neutral
Price Target: $28 → $21
Current: $37.23
Upside: -43.59%
89bio
Oct 12, 2023
Maintains: Buy
Price Target: $36 → $25
Current: $9.66
Upside: +158.80%
uniQure
May 19, 2023
Maintains: Buy
Price Target: $45 → $42
Current: $8.57
Upside: +390.08%
CureVac
Jan 19, 2023
Upgrades: Buy
Price Target: $18
Current: $3.64
Upside: +394.51%
Gossamer Bio
Dec 7, 2022
Maintains: Buy
Price Target: $19 → $8
Current: $1.09
Upside: +633.94%
Monte Rosa Therapeutics
Oct 13, 2022
Initiates: Buy
Price Target: $22
Current: $4.67
Upside: +371.09%
REGENXBIO
Jun 23, 2022
Maintains: Buy
Price Target: $51 → $47
Current: $14.39
Upside: +226.62%
Amicus Therapeutics
May 21, 2021
Initiates: Buy
Price Target: n/a
Current: $10.26
Upside: -
Kymera Therapeutics
May 21, 2021
Initiates: Buy
Price Target: n/a
Current: $44.04
Upside: -
Arvinas
May 21, 2021
Initiates: Buy
Price Target: n/a
Current: $29.52
Upside: -
Galapagos NV
Aug 19, 2020
Maintains: Neutral
Price Target: n/a
Current: $27.39
Upside: -